We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Bipartisan Bill Would Extend Exclusivity, Speed Review of Some Combo Drugs
Bipartisan Bill Would Extend Exclusivity, Speed Review of Some Combo Drugs
October 10, 2012
New fixed-dose drug combinations that include at least two INDs and target a serious or life-threatening disease could be eligible for an additional six months of marketing exclusivity and priority review under a new bipartisan-supported bill sponsored by Rep. Brian Bilbray (R-Calif.).